COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

HLT Meridian Valve CE Mark Trial (RADIANT CE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03805711
Recruitment Status : Terminated (Sponsor decision to stop enrollment.)
First Posted : January 16, 2019
Last Update Posted : May 19, 2020
Information provided by (Responsible Party):
HLT Inc.

Brief Summary:
To evaluate the safety and performance of the HLT System in patients with symptomatic heart disease due to severe aortic stenosis who are judged by the Heart Team to be at Intermediate or High Risk for aortic valve replacement surgery.

Condition or disease Intervention/treatment Phase
Aortic Valve Stenosis Device: HLT® Transcatheter System Not Applicable

Detailed Description:
Prospective, non-randomized, single arm, multi-center CE Mark trial.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Transfemoral Replacement of Aortic Valve With HLT MeriDIAN Valve CE Mark Trial
Actual Study Start Date : July 12, 2019
Actual Primary Completion Date : September 20, 2019
Actual Study Completion Date : September 20, 2019

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Aortic Valve Replacement with HLT® Transcatheter System
Replacement of aortic valve using the HLT® Transcatheter System (HLT System) comprised of The Meridian® II Valve with TriVent™ Anticalcification Treatment and The Pathfinder® II Delivery System
Device: HLT® Transcatheter System
Transcatheter aortic valve replacement using The HLT® Transcatheter System (HLT System) in patients with symptomatic heart disease due to severe aortic stenosis who are judged by the Heart Team to be at Intermediate or High Risk for aortic valve replacement surgery (Heart Team agrees that the risk of 30-day mortality is ≥ 3%).

Primary Outcome Measures :
  1. All-cause mortality [ Time Frame: 30 days ]
    Freedom from all-cause mortality

Secondary Outcome Measures :
  1. Procedural Device Performance [ Time Frame: During the Procedure ]

    Device implant success defined as:

    Absence of procedural mortality AND, Correct positioning of a single prosthetic heart valve into the proper anatomical location AND, Intended performance of the prosthetic heart valve (no prosthesis-patient mismatch and mean aortic valve gradient <20mmHg or peak aortic valve velocity <3 m/sec, AND no moderate or severe AR)

  2. Post-procedural Valve Performance [ Time Frame: 14 Days (or earlier if discharged prior to post-op Day 14), 30 Days, 6 months, 12 months, 24 months, 36 months, 48 months and 60 months ]

    Valve performance will be evaluated by an independent Echo Core Laboratory for the following hemodynamic parameters:

    • Aortic valve area (AVA)
    • Aortic valve regurgitation (AR)
    • Aortic valve gradient (Mean and Peak)

  3. Rate of Adverse Events [ Time Frame: Throughout the 5-year follow-up period, assessed annually at a minimum ]
    • All adverse events through the one (1) year follow up period
    • All Serious Adverse Events through the five (5) year follow up period
    • Major Adverse Cardiovascular and Cerebrovascular Events (MACCE) at 30 Days, 6 months, 12 months and annually through five (5) years

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Echocardiographic or hemodynamic based evidence of severe aortic stenosis with one of the following:

    1. Aortic valve area ≤ 1.0 cm^2 or 0.6 cm^2/m^2
    2. Mean aortic valve gradient ≥ 40 mmHg
    3. Peak aortic valve velocity ≥ 4 m/sec
  • Symptoms due to severe aortic stenosis resulting in one of the following:

    1. NYHA Functional Classification of II or greater
    2. Presence of angina
    3. Presence of syncope
  • Documented aortic valve annular size of ≥ 24 and ≤ 26 mm (associated perimeter range is 76-81mm or associated area range of 453-530 mm2) by the MSCT Core Lab assessment of pre-procedure imaging.
  • Patient is considered intermediate or high risk to undergo surgical aortic valve replacement with one of the following:

    1. Intermediate Surgical Risk: STS-PROM score of ≥ 3% to 8%
    2. High Surgical Risk: STS-PROM score of ≥ 8%
    3. Documented heart team agreement of risk for surgical aortic valve replacement (SAVR) due to other factors not captured by risk-scores (i.e. frailty or comorbidities)
  • Geographically available, willing to comply with follow up and able to provide written informed consent

Exclusion Criteria:

  • Patients with a coronary height of <10mm, or otherwise determined to be at high risk for coronary obstruction
  • Patients with low flow/low gradient aortic stenosis
  • Patients with significant annular or LVOT calcification that could compromise procedural success
  • Pre-existing prosthetic heart valve in any position, or prosthetic ring
  • Severe aortic, mitral or tricuspid valve regurgitation
  • Untreated clinically significant coronary artery disease requiring revascularization
  • Unfavorable peripheral vascular anatomy or disease (e.g. severe obstructive calcification or severe tortuosity) that would preclude passage of 18 Fr catheters from the femoral arterial access to the aorta as evidenced by peripheral MSCT
  • Need for emergent surgery or intervention other than the investigational procedure

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03805711

Layout table for location information
Canada, Quebec
Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Québec
Québec City, Quebec, Canada, G1V 4G5
Sponsors and Collaborators
HLT Inc.
Layout table for investigator information
Principal Investigator: Axel Linke, MD Klinik für Innere Medizin und Kardiologie, Herzzentrum Dresden Universitätsklinik
Layout table for additonal information
Responsible Party: HLT Inc. Identifier: NCT03805711    
Other Study ID Numbers: HLT 1801
First Posted: January 16, 2019    Key Record Dates
Last Update Posted: May 19, 2020
Last Verified: May 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Keywords provided by HLT Inc.:
Aortic Stenosis
Transcatheter Aortic Valve Replacement
Aortic Valve
Additional relevant MeSH terms:
Layout table for MeSH terms
Aortic Valve Stenosis
Heart Valve Diseases
Heart Diseases
Cardiovascular Diseases
Ventricular Outflow Obstruction